NUTX
Nutex Health, Inc.
NUTX has the edge over UNH overall, supported by stronger fundamentals and stronger valuation.
UNH
UnitedHealth Group Incorporated
UNH has lower modeled downside risk, despite its lower overall score.
NUTX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Strong | |
| Strong | |
| Strong |
NUTX's profitability, cash flow and balance sheet are currently strong, but its revenue is under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
NUTX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 6.4x | $171 | — |
| Current | 7.2x | $171 | — |
| Cheap | 7.3x | $174 | +1.7% |
| Fair | 8.7x | $208 | +21% |
| Expensive | 11x | $255 | +49% |
Historical ranges are pointers, not guarantees.
NUTX has the edge over UNH in the historical PE scenario, which offers more potential upside but is not a forecast.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
NUTX Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect NUTX's earnings to grow and its profitability to improve, with its revenue holding steady.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
NUTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $26.68 | +11% |
| Q3 2026 | $23.95 | +24% |
| Q2 2026 | $26.00 | +166% |
| Q1 2026 | $13.67 | +8% |
| Q4 2025 | $10.48 | +14% |
| Q3 2025 | $19.26 | +$28.65 |
| Q2 2025 | $9.78 | +$18.95 |
| Q1 2025 | $12.66 | +$23.26 |
| Q4 2024 | $9.23 | +$21.23 |
NUTX has the edge over UNH on earnings, with more consistent year-over-year improvement.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
NUTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $217.6M | -19% |
| Q2 2026 | $210.8M | -14% |
| Q1 2026 | $216.5M | +2.2% |
| Q4 2025 | $151.7M | -41% |
| Q3 2025 | $267.8M | +240% |
| Q2 2025 | $244M | +221% |
| Q1 2025 | $211.8M | +214% |
| Q4 2024 | $257.6M | +270% |
NUTX's revenue has slid since its 2025 peak: $218M last quarter, down 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 35% | -13 points |
| Q2 2026 | 58% | +44 points |
| Q1 2026 | 38% | -0.6 points |
| Q4 2025 | 20% | -24 points |
| Q3 2025 | 49% | +36 points |
| Q2 2025 | 14% | +6.8 points |
| Q1 2025 | 38% | +36 points |
| Q4 2024 | 44% | +82 points |
NUTX has the edge over UNH on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
NUTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $73.1M | -26% |
| Q2 2026 | $31.7M | +19% |
| Q1 2026 | $74.3M | +46% |
| Q4 2025 | $69M | +$69.3M |
| Q3 2025 | $99.2M | +1507% |
| Q2 2025 | $26.5M | +109% |
| Q1 2025 | $50.9M | +2096% |
| Q4 2024 | -$341.8K | +$608.8K |
NUTX has the edge over UNH on cash flow, with more consistent year-over-year improvement.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
NUTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +20.7K shares |
| 1 year | -1.9% | -136K shares |
| 3 years | +59% | +2.6M shares |
NUTX has the edge over UNH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1,000 |
| Q2 2026 | $19M |
| Q1 2026 | $31.7M |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has 902M diluted shares, down 0.7% from a year ago, with $5B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
NUTX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.6x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.6x | Net Cash |
| Q4 2025 | -0.5x | Net Cash |
| Q3 2025 | -0.3x | Net Cash |
| Q2 2025 | -0.2x | Net Cash |
| Q1 2025 | -0.2x | Net Cash |
| Q4 2024 | -0.0x | Net Cash |
NUTX has the edge over UNH on leverage, with a lower net debt burden relative to earnings.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
NUTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.5 | Neutral |
| Stochastic | 42.9 | Neutral |
NUTX's weekly RSI is 48 (neutral) and its Stochastic is 43 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
NUTX PE vs Healthcare Sector
| Metric | NUTX | Sector median | Relative |
|---|---|---|---|
| PE | 7.2x | 26x | 72% below |
| PE % | 13 | 29 | 16 pts below |
NUTX has the edge over UNH on valuation relative to its sector.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
NUTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $198.8 | 14% below |
| 20 week MA | $187.7 | 8.7% below |
| 50 week MA | $153.5 | 12% above |
| 100 week MA | $123.4 | 39% above |
| 200 week MA | $86.9 | 97% above |
NUTX has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 97% above its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over NUTX on trend strength, trading above more of its moving averages.
NUTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $301.5 | $157.5 | -48% |
| 2021 | $157.5 | $619.5 | +293% |
| 2022 | $619.5 | $312.0 | -50% |
| 2023 | $312.0 | $27.0 | -91% |
| 2024 | $27.0 | $31.9 | +18% |
| 2025 | $31.9 | $176.7 | +455% |
| 2026 YTD | $176.7 | $171.4 | -3% |
NUTX's yearly returns have swung widely, from +455% in 2025 to −91% in 2023. It's down 3% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over NUTX on returns for 2026, with the stronger performance.